| EYLEA HD | Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Phase 3 | Active not recruiting | 311 | Dec 22, 2026 |
| REGN7999 | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | Phase 2 | Active not recruiting | 19 | Dec 3, 2026 |
| Libtayo | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | Phase 2 | Active not recruiting | 151 | Nov 2, 2026 |
| Dupixent | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | Phase 3 | Completed | 880 | Oct 9, 2026 |
| Veopoz | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment | Phase 3 | Completed | 202 | Sep 28, 2026 |
| Dupixent | A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis | Phase 2 | Terminated | 18 | Aug 18, 2026 |
| REGN7041 | A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants | Phase 2 | Terminated | 1 | Jul 21, 2026 |
| mibavademab | A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) | Phase 3 | Completed | 9 | Jul 9, 2026 |
| Ordspono | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies | Phase 2 | Active not recruiting | 515 | Jul 6, 2026 |
| Pasatru | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | Phase 2 | Completed | 1,005 | Jun 16, 2026 |
| baloncibart | Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) | Phase 2 | Completed | 82 | May 6, 2026 |
| REGN5713 | Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy | Phase 3 | Terminated | 24 | May 2, 2026 |
| Aspirin Challenge | Mechanisms of Dupilumab in AERD | Phase 2 | Completed | 16 | Apr 20, 2026 |
| REGN9933 | A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) | Phase 2 | Completed | 195 | Mar 27, 2026 |
| baloncibart | A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension | Phase 2 | Completed | 76 | Feb 1, 2026 |
| Libtayo | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) | Phase 2 | Terminated · results | 1 | Jan 5, 2026 |
| Dupixent | Dupilumab_Metastatic NSCLC | Phase 2 | Completed | 33 | Sep 11, 2025 |
| Praluent | Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) | Phase 3 | Completed | 118 | Aug 24, 2025 |
| Praluent | Cardiac Allograft Vasculopathy Inhibition With Alirocumab | Phase 2 | Completed · results | 114 | Jul 11, 2025 |
| REGN5381 | REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure | Phase 2 | Completed · results | 59 | Jun 2, 2025 |
| Dupixent | Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids | Phase 2 | Completed · results | 20 | May 19, 2025 |
| REGN1908 | A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy | Phase 3 | Completed | 64 | May 10, 2025 |
| REGN5459 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | Phase 2 | Completed | 43 | May 1, 2025 |
| REGN5713 | A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy | Phase 3 | Completed | 54 | Apr 23, 2025 |
| Libtayo | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Completed · results | 712 | Apr 18, 2025 |
| EYLEA HD | Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 | Phase 3 | Terminated | 16 | Mar 26, 2025 |
| REGN2810 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | Phase 3 | Completed · results | 789 | Feb 27, 2025 |
| Dupixent | Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction | Phase 2 | Completed · results | 199 | Feb 20, 2025 |
| Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept | Anti-VEGF Therapy for Acute Thyroid Eye Disease | Phase 2 | Terminated · results | 8 | Dec 17, 2024 |
| REGN7508 | A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants | Phase 2 | Completed · results | 179 | Nov 19, 2024 |
| Libtayo | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | Phase 2 | Terminated · results | 77 | Oct 31, 2024 |
| CMP-001 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | Phase 3 | Terminated · results | 20 | Jul 22, 2024 |
| Dupixent | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | Phase 3 | Completed · results | 106 | Jul 12, 2024 |
| EYLEA HD | Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) | Phase 3 | Completed · results | 35 | May 31, 2024 |
| Libtayo | A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma | Phase 2 | Completed · results | 95 | Feb 16, 2023 |
| Low-Dose REGN4461 | Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy | Phase 2 | Completed · results | 16 | Jan 5, 2022 |
| casirivimab+imdevimab | A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults | Phase 3 | Terminated · results | — | Not stated |